BMN 111
Biological
BioMarin Pharmaceutical Inc.
Total Payments
$4.5M
Transactions
796
Doctors
34
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $3.3M | 536 | 31 |
| 2017 | $1.3M | 260 | 12 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.3M | 579 | 95.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $72,843 | 18 | 1.6% |
| Consulting Fee | $65,213 | 12 | 1.4% |
| Travel and Lodging | $44,876 | 72 | 1.0% |
| Education | $25,923 | 39 | 0.6% |
| Food and Beverage | $8,390 | 74 | 0.2% |
| Honoraria | $8,000 | 2 | 0.2% |
Payments by Type
Research
$4.3M
579 transactions
General
$225,245
217 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia | BioMarin Pharmaceutical Inc. | $1.6M | 2 |
| Multicenter multinational study to collect consistent baseline growth measurements on pediatric patients with Achondroplasia being considered for subsequent enrollment in Study 111-202 No study drug is administered | BioMarin Pharmaceutical Inc. | $757,923 | 0 |
| Multicenter multinational study to collect consistent baseline growth measurements on pediatric patients with Achondroplasia being considered for subsequent enrollment in Study 111-202. No study drug is administered. | BioMarin Pharmaceutical Inc. | $696,607 | 0 |
| A Phase 2, open-label, sequential cohort dose-escalation study of BMN 111 in children with achondroplasia | BioMarin Pharmaceutical Inc. | $547,440 | 0 |
| A Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of BMN 111 in Children With Achondroplasia | BioMarin Pharmaceutical Inc. | $426,993 | 0 |
| A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children with Achondroplasia, Age 0 to 60 Months | BioMarin Pharmaceutical Inc. | $226,113 | 2 |
| A Study to Evaluate Long Term Safety Tolerability Efficacy of BMN 111 in Children With Achondroplasia ACH | BioMarin Pharmaceutical Inc. | $75,527 | 0 |
| Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU Prism302) | BioMarin Pharmaceutical Inc. | $15,450 | 0 |
| An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia | BioMarin Pharmaceutical Inc. | $2,082 | 0 |
Top Doctors Receiving Payments for BMN 111 — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Pediatrics | Minneapolis, MN | $1,016 | 3 |
| , M.D | Orthopaedic Surgery | Santa Monica, CA | $1,000 | 1 |
| , M.D., PH.D | Diagnostic Radiology | Baltimore, MD | $546.50 | 3 |
| , M.D | Internal Medicine | Los Angeles, CA | $359.54 | 5 |
| , DO | Psychiatry | Sylva, NC | $223.28 | 1 |
| , M.D | Obstetrics & Gynecology | Washington, DC | $88.50 | 1 |
| , MD | Pediatrics | Danville, PA | $88.50 | 1 |
| , M.D | Clinical Genetics (M.D.) | Baltimore, MD | $88.50 | 1 |
| , M.D | Obstetrics & Gynecology | Lutherville, MD | $88.50 | 1 |
| , M.D | Molecular Genetic Pathology | New York, NY | $18.92 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Biological
- Total Payments $4.5M
- Total Doctors 34
- Transactions 796
About BMN 111
BMN 111 is a biological associated with $4.5M in payments to 34 healthcare providers, recorded across 796 transactions in the CMS Open Payments database. The primary manufacturer is BioMarin Pharmaceutical Inc..
Payment data is available from 2017 to 2018. In 2018, $3.3M was paid across 536 transactions to 31 doctors.
The most common payment nature for BMN 111 is "Unspecified" ($4.3M, 95.0% of total).
BMN 111 is associated with 9 research studies, including "A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia" ($1.6M).